Kenneth W. Duncan

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing

Sarah V. Gerhart, Wendy A. Kellner, Christine Thompson et al. · Scientific Reports · 2018 · 208 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666

Kenneth W. Duncan, Nathalie Rioux, P. Ann Boriack‐Sjodin et al. · ACS Medicinal Chemistry Letters · 2015 · 151 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

Allison E. Drew, Oscar Moradei, Suzanne L. Jacques et al. · Scientific Reports · 2017 · 136 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies

John W. Lampe, Joshua S. Alford, P. Ann Boriak-Sjodin et al. · ACS Medicinal Chemistry Letters · 2021 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14